ReviewFrontiers in pharmacology2020
Pharmacological Interventions for Bacterial Prostatitis.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- The Role of ButirprostMedicina (Kaunas, Lithuania) · 2025Trial
- Antibiotic Pharmacokinetics and Prostate Penetration in Bacterial Prostatitis: A Systematic Review.Infectious diseases and therapy · 2026Review
- Could Urology's Antimicrobial Stewardship Be Enhanced by the Routine Use of the Meares and Stamey Test?Diagnostics (Basel, Switzerland) · 2025Review
- From Inflammation to Infertility: How Oxidative Stress and Infections Disrupt Male Reproductive Health.Metabolites · 2025Review
- Efficacy of Willow Herb (Antibiotics (Basel, Switzerland) · 2025Article
- Inflammation of the male reproductive system: clinical aspects and mechanisms.Frontiers in endocrinology · 2025Review
- Article
- Fabrication and application of targeted ciprofloxacin nanocarriers for the treatment of chronic bacterial prostatitis.International journal of pharmaceutics: X · 2024Article
- Antibiotic Use in Hospital Urinary Tract Infections After FDA Regulation.Journal of general internal medicine · 2024Article
- Updated Review on Clinically-Relevant Properties of Delafloxacin.Antibiotics (Basel, Switzerland) · 2023Review
- Glucocorticoid nanoformulations relieve chronic pelvic pain syndrome and may alleviate depression in mice.Journal of nanobiotechnology · 2023Article
- Enterococcal Urinary Tract Infections: A Review of the Pathogenicity, Epidemiology, and Treatment.Antibiotics (Basel, Switzerland) · 2023Review
- The Efficacy of FlogofilmJournal of clinical medicine · 2023Article
- Case report: Successful treatment of recurrentFrontiers in pharmacology · 2023Article
- Chemotherapeutic Drugs Induce Different Gut Microbiota Disorder Pattern and NOD/RIP2/NF-κB Signaling Pathway Activation That Lead to Different Degrees of Intestinal Injury.Microbiology spectrum · 2022Article
- Registered Drug Packs of Antimicrobials and Treatment Guidelines for Prostatitis: Are They in Accordance?Healthcare (Basel, Switzerland) · 2022Article
- Antibiotic therapy of chronic bacterial prostatitis is more effective considering antibiotic susceptibility of all pathogens isolated.Investigative and clinical urology · 2022Observational
- Article
- The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review.The world journal of men's health · 2022Review
- Spectrum of Causative Pathogens and Resistance Rates to Antibacterial Agents in Bacterial Prostatitis.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostatitis is a common urinary tract condition but bring innumerable trouble to clinicians in treatment, as well as great financial burden to patients and the society. Bacterial prostatitis (acute bacterial prostatitis plus chronic bacterial prostatitis) accounting for approximately 20% among all prostatitis have made the urological clinics complain about the genital and urinary systems all over the world. The international challenges of antibacterial treatment (emergence of multidrug-resistant bacteria, extended-spectrum beta-lactamase-producing bacteria, bacterial biofilms production and the shift in bacterial etiology) and the transformation of therapeutic strategy for classic therapy have attracted worldwide attention. To the best of our knowledge currently, there is not a single comprehensive review, which can completely elaborate these important topics and the corresponding treatment strategy in an effective way. This review summarizes the general treatment choices for bacterial prostatitis also provides the alternative pharmacological therapies for those patients resistant or intolerant to general treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.